HEAD AN NECK SQUAMOUS CELL CANCERS – EMERGING TARGETED THERAPIES

HEAD AN NECK SQUAMOUS CELL CANCERS – EMERGING TARGETED THERAPIES Systemic therapy remains the cornerstone of treatment for recurrent and metastatic (R/M) head and neck squamous cell cancers (HNSCC). However, there is a dearth of effective treatments beyond platinum combinations, anti-programmed death-1 (PD-1) agents and the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab. Recent […]